6MQD
Myotoxin II from Bothrops moojeni complexed with Rosmarinic Acid
6MQD の概要
エントリーDOI | 10.2210/pdb6mqd/pdb |
分子名称 | Basic phospholipase A2 homolog 2, (2R)-3-(3,4-dihydroxyphenyl)-2-{[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}propanoic acid (3 entities in total) |
機能のキーワード | rosmarinic acid, snake venom, toxin |
由来する生物種 | Bothrops moojeni (Lance-headed viper) |
タンパク質・核酸の鎖数 | 2 |
化学式量合計 | 28184.74 |
構造登録者 | |
主引用文献 | Salvador, G.H.M.,Cardoso, F.F.,Gomes, A.A.,Cavalcante, W.L.G.,Gallacci, M.,Fontes, M.R.M. Search for efficient inhibitors of myotoxic activity induced by ophidian phospholipase A2-like proteins using functional, structural and bioinformatics approaches. Sci Rep, 9:510-510, 2019 Cited by PubMed Abstract: Ophidian accidents are considered an important neglected tropical disease by the World Health Organization. Particularly in Latin America, Bothrops snakes are responsible for the majority of the snakebite envenomings that are not efficiently treated by conventional serum therapy. Thus, the search for simple and efficient inhibitors to complement this therapy is a promising research area, and a combination of functional and structural assays have been used to test candidate ligands against specific ophidian venom compounds. Herein, we tested a commercial drug (acetylsalicylic acid, ASA) and a plant compound with antiophidian properties (rosmarinic acid, RA) using myographic, crystallographic and bioinformatics experiments with a phospholipase A-like toxin, MjTX-II. MjTX-II/RA and MjTX-II/ASA crystal structures were solved at high resolution and revealed the presence of ligands bound to different regions of the toxin. However, in vitro myographic assays showed that only RA is able to prevent the myotoxic effects of MjTX-II. In agreement with functional results, molecular dynamics simulations showed that the RA molecule remains tightly bound to the toxin throughout the calculations, whereas ASA molecules tend to dissociate. This approach aids the design of effective inhibitors of PLA-like toxins and, eventually, may complement serum therapy. PubMed: 30679550DOI: 10.1038/s41598-018-36839-6 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (1.6 Å) |
構造検証レポート
検証レポート(詳細版)をダウンロード